EGFR and non-small cell lung carcinoma: As part of phase I clinical trial CheckMate 012, twenty who have received with erlotinib and one TKI-naive EGFR-mutant NSCLC patients were treated with nivolumab plus erlotinib, and the trial concluded that nivolumab plus erlotinib was tolerable and made durable responses in EGFR-mutant, TKI-treated NSCLC patients (96, 97).